Drug Profile
Research programme: atherosclerosis therapy - Groupe Fournier
Alternative Names: Atherosclerosis therapy research programme - Groupe FournierLatest Information Update: 30 Mar 2001
Price :
$50
*
At a glance
- Originator Groupe Fournier
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 30 Mar 2001 Discontinued-Preclinical for Atherosclerosis in France (Unknown route)
- 29 Dec 1999 The compounds are available for licensing (http://www.groupe-fournier.com/)
- 15 Nov 1999 Preclinical development for Atherosclerosis in France (Unknown route)